BWA
DGX icon

Basecamp Wealth Advisors’s Quest Diagnostics DGX Stock Holding History

Basecamp Wealth Advisors’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.4K Hold
115
– – ﹤0.01% 746
2026
Q1 		$22.5K Sell
115
-19
-14% -$3.69K ﹤0.01% 787
2025
Q4 		$23.3K Buy
+134
New +$24.4K 0.01% 742

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Basecamp Wealth Advisors's DGX Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Quest Diagnostics (DGX) position steady in Q2 2026 at 115 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #746.

Basecamp Wealth Advisors first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Basecamp Wealth Advisors held 115 shares of Quest Diagnostics worth $24.4K as of Q2 2026.
  • Basecamp Wealth Advisors left its Quest Diagnostics share count unchanged in Q2 2026.
  • Quest Diagnostics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #746 holding.
  • Basecamp Wealth Advisors first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • 1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.